Introduction:
Data on progression of recovery after aneurysmal subarachnoid hemorrhage (aSAH) is rare and limited to small samples. We sought to characterize recovery after SAH in a secondary analysis of six SAH trials.
Methods:
Individual data on 3,717 patients from CONSCIOUS-1, ISAT, IHAST, trials of erythropoietin and statins, NEWTON-1, and NEWTON-2 was included. Outcome was described with the Glasgow Outcomes Scale (GOS). Proportions of GOS scores between the first and second time-point were compared using chi-square tests. Rates of improvement (final GOS > initial GOS), no change (final GOS = initial GOS), and worsening (final GOS < initial GOS) and the differences between initial and final GOS scores were calculated.
Results:
There were improvements in outcomes across the entire cohort (p<0.001) and from 30 days to three months (p<0.001), discharge to three months (p<0.001), six weeks to three months (p<0.001), and two months to one year (p<0.001). 907 (26%) of patients improved their outcome, while 2,228 (64%) had no change and 336 (9.7%) worsened. Of the 907 who improved, 773 (85%) improved by one GOS point, 128 (14%) improved by two points, and six (0.7%) improved by three points. Of patients with initial GOS scores of 2, 62 (38%) remained unchanged, while 91 (55%) improved and 11 (6.7%) died. Patient cohorts with initial WFNS grades of 1 (p<0.001), 2 (p<0.001), 3 (p=0.004), and 4 (p<0.001) improved their GOS scores.
Conclusions:
Across most time-frames, many SAH patients can be expected to recover, while a few will regress. Furthermore, even patients with the poorest initial neurological grades and outcomes showed improvement.